Abstract
The time-kill curves of LB20304, a novel fluoroquinolone that has potent antibacterial activity against gram-positve and gram-negative bacteria, were calculated at the concentration of 1/4-, 1/2-, 1-, 2- and 4-times the MIC againstStaphylococcus aureus 77, Escherichia coli, 3739E,Pseudomonas aeruginosa 1912E. The bactericidal activity of LB20304 for these strains was very rapid and comparable to that of ciprofloxacin. LB20304 produced a decrease in the log10 CFU per milliliter of ≥3 within 2 h at 4-times the MIC for all strains and consitently prevented regrowth of bacteria after 24 h of incubation. The MBCs (Minimal Bactericidal Concentration) of LB20304 against test organisms were equal to or at most four-times higher than the MICs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References Cited
Blumberg, H. M., Caroll, D. D. J., Terry, P. and Wachsmuth, I. K., Rapid development of ciprofloxacin resistance in methicillin-susceptible and-resistantStaphylococcus aureus.J. Infect. Dis., 163, 1279–1285 (1991).
Fuchs, P. C., Barry, A. L., Pfaller, M. A., Allen, S. D. and Gerlach, E. H., Multicenter evaluation of thein vitro activities of three new quinolones, sparfloxacin, CI-960, and PD-131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.Antimicrobial Agents and Chemotheraphy, 35, 764–766 (1991).
Hooper, D. C. and Wolfson, J. S., Mechanisms of quinolone action and bactericidal killing, In Hooper, D. C. and Wolfson, J. S. (Eds.),Quinolone antimicrobial agents. American Society for Microbiology, Washington, D.C., 1993, pp. 53–75.
Hooper, D. C., Quinolone mode of action.Drugs 49 (Suppl. 2), 10–15 (1995).
Kim, M. Y., Oh, J. I., Paek, K. S., Hong, C. Y., Kim, I. C. and Kwak, J. H.,In vitro activities of LB20304, a new fluoroquinolone.Arch. Pharm. Res. 19, 52–59 (1996).
National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. M26-T. NCCLS, Villanova, Pa. (1992).
National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Third edition; Approved standard M7-A3. NCCLS, Villanova, Pa. (1993).
Oh, J. I., Paek, K. S., Kim, M. Y., Seo, S. M., Lee, Y. H., Hong, C.-Y., Nam, D. H., Kim, Y. Z., Kim, I. C. and Kwak, J. H.,In vitro andin vivo antibacterial activities of LB20304, a new fluoronaphthyridone. InAbstracts of the 35th Interscience Conference on Antimicrobial agents and Chemotherapy, San Francisco, CA, 1995. Abstract F205, p. 148. American Society for Microbiology, Washington, D.C. (1995).
Oh, J. I., Paek, K. S., Ahn, M. J., Kim, M. Y., Hong, C. Y., Kim, I. C. and Kwak, J. H.,In vitro andin vivo evaluations of LB20304, a new fluoronaphthyridone.Antimicrobial Agents and Chemotheraphy, 40, 1564–1568 (1996).
Paek, K. S., Ahn, M. J., Kim, M. Y., Kim, I. C. and Kwak, J. H., Factors affectingin vitro activity of LB 20304, a new fluoroquinolone.Arch. Pharm. Res. 19, 143–147 (1996).
Piddock, L. J. B., New quinolones and gram-positive bacteria.Antimicrobial Agents and Chemotheraphy, 38, 163–169 (1994).
Raviglione, M. C., Boyle, J. F., Mariuz, P., Pablos-Mendez, A., Cotes, H. and Merlo, A., Ciprofloxacin-resistant methicillin-resistantStaphylococcus aureus in an acute-care hospital.Antimicrobial Agents and Chemotheraphy, 34, 2050–2054 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Paek, KS., Kim, MY., Kim, IC. et al. Bactericidal activities of LB20304, a new fluoroquinolone. Arch. Pharm. Res. 19, 317–320 (1996). https://doi.org/10.1007/BF02976248
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976248